Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 20, 2026

  1. Notable: Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder Enrollment reduced: 180 → 120 participants New York State Psychiatric InstitutePhase 2/3 NCT05011266
  2. Notable: Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER) Enrollment reduced: 1944 → 1117 participants Instituto de Investigación Marqués de ValdecillaPhase 4 NCT07611747
  3. Notable: Implementation of Indocyanine Green to Identify Sentinel Lymph Nodes During Surgery for Breast Cancer Enrollment reduced: 1760 → 1150 participants Isabelle HenskensNot applicable NCT07146295
  4. Notable: Effects and Safety of CT-P51 and Keytruda · Previously Untreated Metastatic Lung Cancer Primary endpoint(s) modified CelltrionPhase 3 NCT06939595
  5. Notable: Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis Results posted: Nov 19, 2026 Bausch Health Americas, Inc.Phase 3 NCT05071716
  6. Notable: Outcomes of Efgartigimod PH20 SC · New-onset Generalized Myasthenia Gravis (gMG) Primary endpoint(s) modified argenxPhase 4 NCT06909214
  7. Notable: SOA101 · Advanced Solid Tumors Primary endpoint(s) modified Shine-On Biomedical Co., Ltd.Phase 1/2 NCT07055594
  8. Notable: NEROFE, a Novel Hormone-Peptide · Advanced MDS and AML Primary completion pushed from Jun 30, 2025 to Dec 31, 2027 Immune System Key LtdPhase 1 NCT04365179
  9. Notable: External Electrical Stimulation for Male Incontinence Results posted: Nov 19, 2026 Elidah, Inc.Not applicable NCT06620419
  10. Notable: Simple-Prep Controlled Embolic Results posted: Nov 19, 2026 Fluidx Medical Technology, Inc.Not applicable NCT06453642
  11. Notable: Nutrition and Swelling Primary endpoint(s) modified University of California, San FranciscoPhase 2 NCT07899762
  12. Notable: SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept · Newly Diagnosed Pulmonary Arterial Hypertension Primary endpoint(s) modified Philipps University MarburgPhase 2 NCT07266519
  13. Notable: Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy · Advanced Non-small Cell Lung Cancer Primary completion pushed from Aug 31, 2025 to Oct 31, 2028 Second Xiangya Hospital of Central South UniversityPhase 1/2 NCT05979818
  14. Notable: Vinpocetine in Healthy Volunteers Primary and study completion pushed from Jun 1, 2026 to Dec 31, 2026 Stanford UniversityPhase 1 NCT06635746
  15. Notable: Talazoparib + Tazemetostat for mCRPC Results posted: Nov 19, 2026 Dana-Farber Cancer InstitutePhase 1 NCT04846478
  16. Notable: Building Healthy Food Environment in Schools: Evaluating Co-created Interventions in Low Resource Settings. #BetterNutrition4Adolescent Enrollment increased: 2600 → 4464 participants Norwegian University of Science and TechnologyNot applicable NCT07332676
  17. Notable: Automated, Assistive, Non-Contact Sleep Quality Monitor for Older Adults Recruitment opened Indiana UniversityNot applicable NCT06045988
  18. Notable: BFR and Neuromuscular Training in Knee Osteoarthritis (KOA) Primary endpoint(s) modified University of LahoreNot applicable NCT07942883
  19. Notable: Screen Time Exposure and Behavioral Outcomes Primary endpoint(s) modified Sohag UniversityNot specified NCT07941596
  20. Notable: Cost-Effectiveness of the Healthy Beat Acupunch Regimen in Community-Dwelling Older Adults Primary endpoint(s) modified Mahidol UniversityNot applicable NCT07868575
  21. Notable: Perianchor Cyst Formation, Tendon Healing, and Clinical Outcomes Following Arthroscopic Rotator Cuff Repair Primary endpoint(s) modified Fatih Sultan Mehmet Training and Research HospitalNot specified NCT07661680
  22. Notable: Exercise Intervention to Increase Physical Activity in Young Sarcoma Survivors (Sport Ist Herzenssache) Recruitment opened Universität Duisburg-EssenNot applicable NCT07729059
  23. Notable: Empowered Relief for Caregivers Recruitment opened Stanford UniversityNot applicable NCT07636980
  24. Notable: SHOFU FX-LC RMGI Restoration Versus FUJI II RGMI · Anterior Carious Cervical Lesions Enrollment increased: 36 → 56 participants Cairo UniversityNot applicable NCT07937176
  25. Notable: Systemic Therapy Alone and With Local Ablative Treatment for Stage IV Non-Small Cell Lung Cancer Patients Primary endpoint(s) modified Swiss Cancer InstituteNot applicable NCT06114108